Abstract:Background: Colorectal cancer (CRC) is a high-indence malignance of the digestive system with a high mortality rate in the world. Aim: The results are desired to provide an important theoretical basis for discovering new therapeutic targets for CRC. Objective: The expression of human endogenous retrovirus-H-long terminal repeat association protein 2 (HHLA2) in human CRC was detected to explore its correlationship with clinicopathological features and prognosis of patients and its potential in treating CRC. Methods: Western blot was employed to detect HHLA2 expression in fresh tissues obtained from 6 CRC patients' excisions, including cancer, paracancer, and normal issues. Immunohistochemical staining was employed to determine HHLA2 expression in paraffin-embedded specimens of 139 patients with colorectal cancer, and its relationship with the clinicopathological profiles and survival was analyzed. Small interfering RNA (siRNA) targeting HHLA2 was used to transfect CRC cells to silent HHLA2. MTT, plate colony formation, cell scratch, and Transwell assay were conducted to observe the proliferation, migration, and invasion of CRC cells. result: HHLA2 protein was expressed in human colorectal cancer tissues, paracancer tissues and normal tissues, and its expression significantly upregulated in cancer tissues (P&lt;0.01). HHLA2 expression level in colorectal cancer tissues showed a close correlationship with the invasion depth of tumor (P=0.000), metastasis of regional lymph nodes (P=0.018), clinical stage (P=0.010) and patient survival (P=0.011). No significant correlation was found with gender (P=0.873), age (P=0.864), location of tumor (P=0.768), degree of tumor differentiation (P=0.569) and distant metastasis (P=0.494). Survival analysis showed that the survival time of colorectal cancer patients with high and low HHLA2 expression group was 43.231 months and 55.649 months, respectively, with statistical difference between the two groups (P=0.001). HHLA2 silencing significantly inhibited the proliferation, migration and invasion of CRC cells. Results: HHLA2 protein was expressed in human colorectal cancer tissues, paracancer tissues and normal tissues, which was significantly upregulated in cancer tissues (P<0.01). HHLA2 expression level in CRC tissues showed a close correlationship with the invasion depth of the tumor (P=0.000), metastasis of regional lymph nodes (P=0.018), clinical stage (P=0.010), and patient survival (P=0.011). Correlation with gender (P=0.873), age (P=0.864), location of the tumor (P=0.768), degree of tumor differentiation (P=0.569) and distant metastasis (P=0.494) exhibited no significance. The survival time of CRC patients with high and low HHLA2 expression groups was 43.231 months and 55.649 months, respectively, with a statistical difference between the two groups (P=0.001). Silencing HHLA2 inhibited proliferation, migration and invasion of CRC cells significantly. Conclusion: HHLA2 is overexpressed in CRC tissues which is associated with poor prognosis of patients. HHLA2 might be recognized as a new candidate for adjuvant diagnosis and prognosis of CRC, as well as a promised new target for immunotherapy of CRC. other: no

HLA class II polymorphisms as prognostic biomarkers for right and left-sided colon cancer

Differential role of HLA-A and HLA-B, C expression levels as prognostic markers in colon and rectal cancer

ESR 2 polymorphism associated with the incidence and prognosis of hepatocellular carcinoma

Correlation between hMLH1-93G/A gene polymorphism and colorectal cancer

Class II HLA-DRB4 is a predictive biomarker for survival following immunotherapy in metastatic non-small cell lung cancer

Clinical Significance of HHLA2 as a Novel Therapeutic Target for Colorectal Cancer

Patient HLA Class I Genotype Influences Cancer Response to Checkpoint Blockade Immunotherapy

MHC Class II alleles in ulcerative colitis-associated colorectal cancer

Human Leucocyte Antigens as Prognostic Markers in Head and Neck Squamous Cell Carcinoma

Molecular Differences between Hepatic and Extrahepatic Metastases from Left-Sided and Right-Sided Colorectal Cancer: Potential Metastatic and Prognostic Biomarkers

No Association Between the Polymorphisms in CDX2 Coding Regions and Colorectal Cancer in Chinese

Human Leukocyte Antigen Class I and II Alleles and Cervical Adenocarcinoma.

Integrative Clinical and DNA Methylation Analyses in a Population-Based Cohort Identifies CDH17 and LRP2 as Risk Recurrence Factors in Stage II Colon Cancer

Polymorphism of HLA and Susceptibility of Breast Cancer

Prognostic Significance of Immune Checkpoints HLA-G/ILT-2/4 and PD-L1 in Colorectal Cancer

Discovering the molecular differences between right- and left-sided colon cancer using machine learning methods

Abstract 3014: Association between HLA-KIR allele interaction combinations and density of T-cell subsets in colorectal cancer

Down-regulation of HLA-A expression correlates with a better prognosis in colorectal cancer patients

HLA diversity unveils susceptibility and organ-specific occurrence of second primary cancers: a prospective cohort study

Human Leukocyte Antigen-Allelic Variations May Influence the Age at Cancer Diagnosis in Lynch Syndrome

HLA class II alleles differing by a single amino acid associate with clinical phenotype and outcome in patients with primary membranous nephropathy.